Title Image

R&D

HND-002
Indication ­ ‒ ­Healing of all grades of erosive esophagitis (EE)
­ ‒ ­Maintaining healing of EE
­­‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD)
Status First- to File (FTF), the commercialization partner, Par, received final approval in April 2017.
Product Advantages ­ ‒ FTF, 180-day market exclusivity right in the USA.
­ ‒ settled with the brand company.
Potential Market The market value of branded drug is about $1 billion per year. Par, a commercialization partner of Handa, is expected to occupy a certain market share.